di , 25/10/2023

Patients Benefit from Earlier Detection and Treatment of Health Conditions

ORANGE COUNTY, Calif.–(BUSINESS WIRE)–PHASE Scientific Americas (PHASE Scientific), a fast-growing, global biomedical company developing innovative solutions to revolutionize healthcare diagnostics, announces INDICAID health™, its new line of at-home health tests and digital health experiences. INDICAID health™ meets patients where they are by letting them test from the comfort of their own home and receive care that aligns with their personal situations and suits their lifestyle best.

INDICAID health™ was created to help patients get back to better health faster and with less hassle. At the company’s California CLIA-certified laboratory, Phase Scientific Medical Laboratory, samples are processed by a dedicated team of licensed technicians and results are reviewed and released by the medical director. Results are promptly delivered online in a secure, HIPAA-compliant, and most importantly, easy-to-understand way. Once the test results have been received, all INDICAID health patients can – at no extra cost – connect virtually with a board-certified healthcare provider who can give guidance and treatment options.

“INDICAID health™ supports PHASE Scientific’s mission of shaping the future of at-home, personal diagnostics with people-first, science-based innovations,” said Felix Chao, General Manager of PHASE Scientific Americas. “Digital health solutions are often designed first for maximum efficiency and minimal human-to-human interaction. Warmth and empathy are an afterthought. We’ve designed INDICAID health™ to provide a more personal and compassionate approach to care, combining science and professional guidance, while ensuring a streamlined experience. We aim to be your preferred “back to health” partner, delivering easy testing, accurate diagnoses and compassionate care that result in better outcomes, sooner.”

INDICAID health™ will launch with a menu of tests for respiratory, sexual and women’s health, and add up to eight more tests within the next six months or less. According to the Centers for Disease Control and Prevention (CDC), in 2021 there were more than 2.5 million STI infections in the United States. The INDICAID health™ Sexual Health 2 test checks for the top two common STIs: Chlamydia and Gonorrhea. Its Women’s Health 3 test helps detect common vaginal infections including Trichomoniasis (Trich), Bacterial Vaginosis (BV) and Candidiasis (Yeast Infection) in one test. Given recent spikes in COVID cases across the country, the company’s INDICAID COVID-19 rapid antigen test will also continue to be available on INDICAID health™.

Along with its state-of-the-art tests available for consumers, INDICAID health™ is working with leading healthcare providers, retailers, pharmacies, educational institutions, employers, and public health organizations to bring world-class testing-and-treatment to all communities and empower people with the information they need to lead healthier lives. With an at-home diagnostics market expected to grow to $8.5 billion by 2030, partnering with INDICAID health™ allows you to provide a better back-to-health solution to your customers and patients. Also, INDICAID health™ has an active product development pipeline and will be rolling out additional at-home diagnostics to cover a broad range of health conditions and enable more patients to take their health care journey into their own hands.

Details about INDICAID health™ are available at www.indicaidhealth.com.

About PHASE Scientific Americas

PHASE Scientific Americas is a fast-growing biotechnology company with a mission to inspire a new state of health. We are committed to providing patients and healthcare providers in the Americas and beyond with innovative diagnostic and data tools that will enable them to access better health information and make better health decisions. An affiliate of PHASE Scientific International, headquartered in Hong Kong, we have strategic offices in Orange County, California and Atlanta, Georgia.


Douglas Field

Chief Revenue Officer

(404) 783-9820